Transforming Lives.
Redefining Possibilities.
Featured
Kenneth He Huang Named President and Chief Executive Officer of Pamlico Pharmaceuticals
The Pamlico Board of Directors has unanimously selected Kenneth He Huang as the President and Chief Executive Officer, effective August 11, 2025, when she will also join the Board. This appointment reflects a key milestone in the Board’s long-term succession planning process and previously disclosed CEO transition.
Science Stories
A Turning Point in H3 K27M-mutant Diffuse Midline Glioma
As we deepen our commitment to oncology, we’re focused on bringing forward meaningful innovation for patients, especially those facing rare and aggressive cancers like H3 K27M-mutant diffuse midline glioma. With the FDA approval of the first treatment for this cancer, there is new hope for patients and families who are navigating this life-threatening disease.
Science Stories
The Role of Molecular Testing in H3 K27M-mutant Diffuse Midline Glioma Management
H3 K27M-mutant diffuse midline glioma is a highly aggressive brain tumor most commonly found in children and young adults. Because of poor prognosis associated with this disease due to its deep location in the brain and aggressive biology, early identification and accurate molecular diagnosis are essential to help determine the best treatment course.
Science Stories
The Importance of First-Line Maintenance Therapy in Small Cell Lung Cancer
Scientific advances are reshaping how small cell lung cancer is understood and treated. As interest grows in first-line maintenance strategies, researchers are exploring new ways to extend the impact of initial therapy in this historically difficult-to-treat cancer.
News and Events
Sept 20
Sept 20
Pamlico Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
Sept 20
Pamlico Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
Sept 20
Pamlico Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355